|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.99 USD | -3.91% |
|
-2.50% | +3.50% |
| 05-13 | Surgery Partners Delivered Solid Q1 Beat Amid Stabilizing Portfolio, RBC Says | MT |
| 05-05 | Tranche Update on Surgery Partners, Inc.'s Equity Buyback Plan announced on March 2, 2026. | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 3.3 | 3.58 | 3.82 | 4.01 | 3.74 | |||||
Return on Total Capital | 3.61 | 3.85 | 4.09 | 4.3 | 4.02 | |||||
Return On Equity % | 3.6 | 3.12 | 4.07 | 0.36 | 2.76 | |||||
Return on Common Equity | -13.48 | -3.54 | -0.6 | -8.9 | -4.45 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 22.08 | 22.64 | 23.6 | 23.94 | 23.12 | |||||
SG&A Margin | 4.67 | 4.02 | 4.41 | 4.45 | 3.57 | |||||
EBITDA Margin % | 18.1 | 18.96 | 19.43 | 20.13 | 19.81 | |||||
EBITA Margin % | 13.86 | 14.69 | 15.4 | 15.51 | 14.68 | |||||
EBIT Margin % | 13.66 | 14.44 | 15.12 | 15.23 | 14.49 | |||||
Income From Continuing Operations Margin % | 3.18 | 3.43 | 4.93 | 0.4 | 2.99 | |||||
Net Income Margin % | -3.19 | -2.15 | -0.43 | -5.4 | -2.35 | |||||
Net Avail. For Common Margin % | -3.65 | -2.15 | -0.43 | -5.4 | -2.35 | |||||
Normalized Net Income Margin | -3.71 | -1.83 | 0.01 | 0.06 | -1 | |||||
Levered Free Cash Flow Margin | 0.95 | 0.43 | 5.2 | 5.83 | 4.98 | |||||
Unlevered Free Cash Flow Margin | 7.15 | 6.21 | 9.6 | 9.88 | 10.13 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.39 | 0.4 | 0.4 | 0.42 | 0.41 | |||||
Fixed Assets Turnover | 2.46 | 2.41 | 2.31 | 2.39 | 2.34 | |||||
Receivables Turnover (Average Receivables) | 5.48 | 5.73 | 5.76 | 5.79 | 5.6 | |||||
Inventory Turnover (Average Inventory) | 29.51 | 29.65 | 28.59 | 28.96 | 27.5 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.76 | 1.87 | 1.71 | 1.79 | 1.87 | |||||
Quick Ratio | 1.53 | 1.5 | 1.32 | 1.36 | 1.37 | |||||
Operating Cash Flow to Current Liabilities | 0.16 | 0.32 | 0.56 | 0.48 | 0.45 | |||||
Days Sales Outstanding (Average Receivables) | 66.63 | 63.71 | 63.38 | 63.2 | 65.16 | |||||
Days Outstanding Inventory (Average Inventory) | 12.37 | 12.31 | 12.77 | 12.64 | 13.27 | |||||
Average Days Payable Outstanding | 23.63 | 25.55 | 28.11 | 29.23 | 29.85 | |||||
Cash Conversion Cycle (Average Days) | 55.37 | 50.47 | 48.03 | 46.6 | 48.58 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 145.78 | 90.47 | 91.6 | 102.14 | 114.51 | |||||
Total Debt / Total Capital | 59.31 | 47.5 | 47.81 | 50.53 | 53.38 | |||||
LT Debt/Equity | 141.41 | 87.45 | 88.3 | 98.13 | 110.49 | |||||
Long-Term Debt / Total Capital | 57.54 | 45.91 | 46.09 | 48.54 | 51.51 | |||||
Total Liabilities / Total Assets | 62.41 | 50.87 | 51.11 | 53.93 | 56.56 | |||||
EBIT / Interest Expense | 1.38 | 1.56 | 2.15 | 2.35 | 1.76 | |||||
EBITDA / Interest Expense | 2.25 | 2.41 | 3.21 | 3.56 | 2.73 | |||||
(EBITDA - Capex) / Interest Expense | 1.99 | 2.06 | 2.75 | 3.11 | 2.44 | |||||
Total Debt / EBITDA | 6.75 | 5.25 | 4.98 | 5.18 | 5.43 | |||||
Net Debt / EBITDA | 5.96 | 4.75 | 4.66 | 4.8 | 5.1 | |||||
Total Debt / (EBITDA - Capex) | 7.63 | 6.13 | 5.81 | 5.92 | 6.07 | |||||
Net Debt / (EBITDA - Capex) | 6.74 | 5.54 | 5.44 | 5.49 | 5.71 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 19.62 | 14.12 | 8.03 | 13.52 | 6.24 | |||||
Gross Profit, 1 Yr. Growth % | 29.38 | 16.99 | 12.63 | 15.15 | 2.6 | |||||
EBITDA, 1 Yr. Growth % | 41.63 | 19.51 | 8.93 | 17.38 | 4.56 | |||||
EBITA, 1 Yr. Growth % | 59 | 19.97 | 10.92 | 14.02 | 0.54 | |||||
EBIT, 1 Yr. Growth % | 60.34 | 20.59 | 10.79 | 14.01 | 1.1 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 5.34K | 23.06 | 55.52 | -90.76 | 691.2 | |||||
Net Income, 1 Yr. Growth % | -38.93 | -22.99 | -78.21 | 1.31K | -53.66 | |||||
Normalized Net Income, 1 Yr. Growth % | -30.16 | -43.66 | -100.78 | 86.9 | -1.79K | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | -64.86 | -47.04 | -84.05 | 1.31K | -54.05 | |||||
Accounts Receivable, 1 Yr. Growth % | 12.56 | 6.07 | 8.79 | 16.66 | 3.99 | |||||
Inventory, 1 Yr. Growth % | 8.33 | 16.86 | 5.32 | 17.55 | 9.28 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 11.59 | 21.17 | 5.91 | 13.07 | 4.23 | |||||
Total Assets, 1 Yr. Growth % | 13.01 | 9.23 | 2.91 | 14.74 | 2.91 | |||||
Tangible Book Value, 1 Yr. Growth % | -15.67 | -23.91 | 9.74 | 38.87 | 5.98 | |||||
Common Equity, 1 Yr. Growth % | 842.04 | 83.49 | -0.55 | -9.94 | -4.29 | |||||
Cash From Operations, 1 Yr. Growth % | -64.72 | 82.32 | 85.01 | 2.14 | -8.6 | |||||
Capital Expenditures, 1 Yr. Growth % | 34.27 | 39.93 | 10.17 | 1.8 | -12.94 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -86.43 | -48.45 | 805.95 | 26.57 | -14.34 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -43.42 | -0.93 | 61.98 | 16.49 | 5.26 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 10.23 | 16.84 | 11.04 | 10.74 | 9.82 | |||||
Gross Profit, 2 Yr. CAGR % | 7.68 | 23.03 | 14.79 | 13.88 | 8.7 | |||||
EBITDA, 2 Yr. CAGR % | 9.39 | 30.1 | 15.02 | 12.91 | 10.78 | |||||
EBITA, 2 Yr. CAGR % | 7.92 | 38.52 | 16.56 | 12.25 | 7.07 | |||||
EBIT, 2 Yr. CAGR % | 8.11 | 39.05 | 16.81 | 12.18 | 7.36 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 25.2 | 718.07 | 38.34 | -62.1 | -14.5 | |||||
Net Income, 2 Yr. CAGR % | -2.64 | -31.42 | -59.03 | 75.46 | 155.86 | |||||
Normalized Net Income, 2 Yr. CAGR % | 13.36 | -37.27 | -93.38 | -79.13 | 462.1 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | -30.01 | -56.86 | -70.93 | 49.82 | 154.25 | |||||
Accounts Receivable, 2 Yr. CAGR % | 13.24 | 9.26 | 7.42 | 12.66 | 10.14 | |||||
Inventory, 2 Yr. CAGR % | 14.88 | 12.51 | 10.94 | 11.27 | 13.34 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 7.78 | 16.28 | 13.28 | 9.43 | 8.56 | |||||
Total Assets, 2 Yr. CAGR % | 10.4 | 11.1 | 6.02 | 8.66 | 8.66 | |||||
Tangible Book Value, 2 Yr. CAGR % | -4.65 | -19.9 | -8.62 | 23.45 | 21.31 | |||||
Common Equity, 2 Yr. CAGR % | 91.55 | 315.76 | 35.08 | -5.36 | -7.16 | |||||
Cash From Operations, 2 Yr. CAGR % | -17.99 | -19.8 | 83.66 | 37.47 | -3.38 | |||||
Capital Expenditures, 2 Yr. CAGR % | -11.53 | 37.07 | 24.16 | 5.91 | -5.86 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | -32.48 | -73.59 | 160.43 | 224.35 | 7.18 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 0.36 | -25.13 | 28.62 | 36.91 | 12.66 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 7.9 | 11.51 | 13.83 | 11.86 | 9.22 | |||||
Gross Profit, 3 Yr. CAGR % | 6.21 | 10.7 | 19.46 | 14.91 | 9.99 | |||||
EBITDA, 3 Yr. CAGR % | 7.95 | 12.67 | 23.29 | 15.88 | 10.06 | |||||
EBITA, 3 Yr. CAGR % | 6.16 | 12.11 | 29.53 | 15.81 | 8.2 | |||||
EBIT, 3 Yr. CAGR % | 6.34 | 12.12 | 29.83 | 15.97 | 8.36 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | -9.57 | 24.48 | 370.38 | -43.87 | 4.37 | |||||
Net Income, 3 Yr. CAGR % | -29.89 | -9.96 | -53.2 | 33.34 | 12.58 | |||||
Normalized Net Income, 3 Yr. CAGR % | 29.07 | -10.2 | -85.48 | -71.25 | -9.69 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | -39.07 | -36.22 | -69.03 | 5.94 | 1.03 | |||||
Accounts Receivable, 3 Yr. CAGR % | 10.82 | 10.79 | 9.11 | 10.41 | 9.69 | |||||
Inventory, 3 Yr. CAGR % | 12.08 | 15.53 | 10.06 | 13.1 | 10.6 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 30.79 | 12.07 | 12.72 | 13.21 | 7.67 | |||||
Total Assets, 3 Yr. CAGR % | 9.37 | 10.01 | 8.3 | 8.85 | 6.71 | |||||
Tangible Book Value, 3 Yr. CAGR % | -1.86 | -11.56 | -11.03 | 5.06 | 17.33 | |||||
Common Equity, 3 Yr. CAGR % | 39.1 | 88.82 | 158.08 | 18.01 | -5.01 | |||||
Cash From Operations, 3 Yr. CAGR % | -15.55 | 7.04 | 5.97 | 51.04 | 19.98 | |||||
Capital Expenditures, 3 Yr. CAGR % | 13.11 | 3.07 | 27.44 | 16.21 | -0.79 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -47.22 | -38.35 | -2.74 | 105.09 | 112.15 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -12.18 | -0.07 | -2.17 | 24.55 | 26.88 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 14.69 | 14.11 | 9.14 | 11.2 | 12.21 | |||||
Gross Profit, 5 Yr. CAGR % | 10.37 | 14 | 9.56 | 11.96 | 15.03 | |||||
EBITDA, 5 Yr. CAGR % | 10.43 | 15.91 | 10.73 | 13.24 | 18.18 | |||||
EBITA, 5 Yr. CAGR % | 7.45 | 14.93 | 10.39 | 12.78 | 20.09 | |||||
EBIT, 5 Yr. CAGR % | 8.13 | 15.52 | 10.42 | 12.77 | 20.39 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | -3.64 | 24.83 | 7.19 | -22.63 | 137.82 | |||||
Net Income, 5 Yr. CAGR % | 49.63 | 0.6 | -43.45 | 17.58 | -7.67 | |||||
Normalized Net Income, 5 Yr. CAGR % | 54.8 | 14.09 | -60.65 | -50.23 | -22.45 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 41.61 | -18.4 | -54.68 | -10.25 | -28.11 | |||||
Accounts Receivable, 5 Yr. CAGR % | 13.58 | 9.07 | 9.45 | 11.54 | 9.52 | |||||
Inventory, 5 Yr. CAGR % | 16.25 | 9.7 | 11.62 | 13.81 | 11.36 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 36.1 | 23.73 | 23.48 | 11.01 | 11.04 | |||||
Total Assets, 5 Yr. CAGR % | 21.56 | 7.65 | 8.02 | 9.47 | 8.45 | |||||
Tangible Book Value, 5 Yr. CAGR % | 12.46 | -4.54 | -4.62 | 1.06 | 0.72 | |||||
Common Equity, 5 Yr. CAGR % | 157.19 | 25 | 37.48 | 43.24 | 71.46 | |||||
Cash From Operations, 5 Yr. CAGR % | -7.01 | 5.61 | 15.23 | 18.3 | 2.13 | |||||
Capital Expenditures, 5 Yr. CAGR % | 8.05 | 22.18 | 17.41 | 4.2 | 12.9 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -9.55 | -26 | -0.05 | 31.5 | 1.21 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 10.27 | 5.21 | 2.31 | 14.25 | 3.57 |
- Stock Market
- Stocks
- SGRY Stock
- Financials Surgery Partners, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















